This inventor holds 3 USPTO granted patents and 2 EPO patents. Top assignee: Novagali Pharma Sa. Active years: 2012-2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Marcoussis, FR (2012)
- Epinay sur Orge, FR (2012 - 2013)
Company Filing History:
Years Active: 2012-2013
Title: Séverine Bague: Innovator in Ophthalmic Emulsions
Introduction
Séverine Bague is a prominent inventor based in Epinay sur Orge, France. She has made significant contributions to the field of ophthalmology through her innovative work on emulsions. With a total of 3 patents to her name, her inventions focus on improving the delivery of pharmaceutical drugs through advanced emulsion technology.
Latest Patents
One of her latest patents is an "Ophthalmic oil-in-water type emulsion with stable positive zeta potential." This invention includes colloid particles with an oily core surrounded by an interfacial film. The emulsion contains at least one cationic agent and one non-ionic surfactant, achieving a positive zeta potential that meets specific stability requirements. Another notable patent is the "Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential." This well-tolerated emulsion serves as a delivery vehicle for hydrophobic ingredients, including pharmaceutical drugs, and comprises a minimal concentration of cationic agents.
Career Highlights
Séverine Bague is currently associated with Novagali Pharma, a company known for its focus on innovative ophthalmic solutions. Her work has been instrumental in advancing the field of drug delivery systems, particularly in ophthalmology.
Collaborations
She collaborates with talented individuals such as Betty Philips and Laura Rabinovich-Guilatt, contributing to a dynamic and innovative work environment.
Conclusion
Séverine Bague's contributions to ophthalmic emulsions highlight her role as a leading inventor in the field. Her patents reflect a commitment to enhancing drug delivery systems, ultimately benefiting patients and the medical community.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile